{"entity":{"id":"nct06040541","kind":"trial","name":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","aka":["RMC-9805-001"],"tldr":"A phase 1 trial of zoldonrasib (RMC-9805) alone or with daraxonrasib (RMC-6236) in KRAS G12D-mutant solid tumours, including pancreatic, bowel and non-small-cell lung cancer, run by Revolution Medicines, now recruiting.","summary":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors is a phase 1/1b interventional study registered as NCT06040541 by Revolution Medicines, Inc., with an estimated 604 participants across the whole study. Two arms are recorded: RMC-9805 (zoldonrasib) monotherapy and RMC-9805 plus RMC-6236 (daraxonrasib). Conditions listed: non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma and advanced solid tumours. The registry carries no results; the combination cohort figures reported by the sponsor at ESMO GI 2026 sit on the pairing record g12d-plus-pan-ras.","status":"recruiting","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT06040541","url":"https://clinicaltrials.gov/study/NCT06040541"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","colorectal","nsclc"],"sections":[],"technologies":[],"targets":["kras"],"drugs":["zoldonrasib","daraxonrasib"],"companies":["revolution-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06040541","phase":"1","setting":"Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors","sponsor":"Revolution Medicines, Inc.","enrolled":604,"outcomes":[]},"route":"/trials/nct06040541/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/"},{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/"}],"company":[{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/"}],"pairing":[{"id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/"}]}}